Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
Predicting adverse events of cancer medicines: a secondary analysis of clinical trial data
- At: 2017 FIP Congress in Stockholm (Sweden)
- Type: Poster
- By: SORICH, Michael (Flinders University, Adelaide, Australia)
- Co-author(s): Michael Sorich: Clinical Pharmacology, Flinders University, Adelaide, Australia
Andrew Rowland: Clinical Pharmacology, Flinders University, Adelaide, Australia
Ganessan Kichenadasse: Flinders Centre for Innovation in Cancer, Flinders University, Adelaide, Australia
Richard Woodman: Flinders Centre for Epidemiology and Biostatistics, Flinders University, Adelaide, Australia
Arduino Mangoni: Clinical Pharmacology, Flinders University, Adelaide, Australia
BackgroundsSecondary analysis of pooled clinical trial data is an important means of identifying patient characteristics and laboratory/biological markers that predict individuals at greatest risk of toxicities from cancer medicines.
AimsTo evaluate risk factors for proteinuria in patients with metastatic renal cell carcinoma (mRCC) treated with a .. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019